EAH.LSE Eco Animal Health Group Plc
- Market cap
- GBX 63.1M
- P/E
- 31.5x
- P/B
- 0.72x
- ROE
- 2.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Mar 2026.
Is EAH.LSE undervalued?
Graham numberEAH.LSE trades 0.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Eco Animal Health Group Plc fundamental analysis
No fundamental analysis for Eco Animal Health Group Plc yet.
Eco Animal Health Group Plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Eco Animal Health Group Plc
ECO Animal Health Group plc, together with its subsidiaries, manufactured and supply animal health products internationally. The company provides Aivlosin, a macrolide antibiotic for the treatment of enteric and respiratory diseases in pigs and poultry. It also offers Ecomectin to treat parasites in cattle, sheep, and pigs; and ECOVAXXIN MS, a mycoplasma solution. ECO Animal Health Group plc was founded in 1972 and is based in London, the United Kingdom.
Full company profileEco Animal Health Group Plc financial statements
Eco Animal Health Group Plc annual financial statements (GBP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 61.4M | 67.2M | 67.3M | 72.1M | 106M | 82.2M | 85.3M | 89.4M | 79.6M | 87.5M |
| Gross Profit | 30.3M | 32.2M | 31.8M | 32.4M | 51.5M | 33.7M | 36.8M | 37.7M | 35.9M | 42.5M |
| Operating Income | 12.9M | 14.1M | 10.1M | 6.51M | 16.9M | 4.53M | 5.06M | 3.54M | 4.30M | 5.40M |
| EBITDA | 16.3M | 17.6M | 12.7M | 7.60M | 18.6M | 3.62M | 7.41M | 6.53M | 7.29M | 8.06M |
| Net Income | 10.6M | 9.32M | 7.25M | 3.90M | 7.34M | -686K | 1.01M | 1.05M | 1.69M | 2.19M |
| EPS | 0.16 | 0.14 | 0.11 | 0.06 | 0.11 | -0.01 | 0.01 | 0.02 | 0.02 | 0.03 |
| Balance Sheet | ||||||||||
| Total Assets | 114M | 117M | 106M | 100.0M | 117M | 114M | 121M | 123M | 121M | 119M |
| Total Liabilities | 15.6M | 12.3M | 16.5M | 19.5M | 21.6M | 19.3M | 25.8M | 29.9M | 25.8M | 23.1M |
| Shareholders' Equity | 93.8M | 99.7M | 84.5M | 74.7M | 81.9M | 82.1M | 83.3M | 83.7M | 85.5M | 87.1M |
| Cash & Short-term Investments | 20.6M | 21.3M | 16.9M | 11.9M | 19.5M | 14.3M | 21.7M | 22.4M | 25.0M | 25.4M |
| Total Debt | - | - | 1.77M | 3.80M | 1.52M | 1.91M | 4.48M | 4.03M | 3.79M | 4.93M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 11.8M | 14.1M | 6.27M | 4.40M | 12.0M | -548K | 15.9M | 9.42M | 10.4M | 7.73M |
| Capital Expenditure | 265K | 324K | 566K | 2.88M | 1.07M | 2.89M | 5.98M | 4.62M | 5.00M | 192K |
| Free Cash Flow | 11.6M | 13.7M | 5.71M | 1.52M | 10.9M | -3.44M | 9.93M | 4.79M | 5.44M | 7.54M |
| Ratios | ||||||||||
| ROE | 11.3% | 9.3% | 8.6% | 5.2% | 9.0% | -0.8% | 1.2% | 1.3% | 2.0% | 2.5% |
| ROA | 9.3% | 7.9% | 6.8% | 3.9% | 6.3% | -0.6% | 0.8% | 0.9% | 1.4% | 1.8% |
| Net Profit Margin | 17.2% | 13.9% | 10.8% | 5.4% | 6.9% | -0.8% | 1.2% | 1.2% | 2.1% | 2.5% |
| Debt to Equity | - | - | 0.02x | 0.05x | 0.02x | 0.02x | 0.05x | 0.05x | 0.04x | 0.06x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Eco Animal Health Group Plc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- 113.9%
- Ex-dividend date
- Sep 23, 2021
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | GBP 2.49M | 0.04 | 113.9% |
| 2025 | GBP 1.07M | 0.02 | 63.2% |
| 2024 | GBP 2.81M | 0.04 | 268.4% |
| 2023 | GBP 1.81M | 0.03 | 179.6% |
| 2022 | GBP 2.89M | 0.04 | - |
| 2021 | GBP 562K | 0.01 | 7.7% |
| 2020 | GBP 8.42M | 0.12 | 216.2% |
| 2019 | GBP 10.1M | 0.15 | 139.5% |
| 2018 | GBP 6.05M | 0.09 | 64.9% |
| 2017 | GBP 4.25M | 0.07 | 40.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 3:1 on Oct 18, 2002.
Who owns Eco Animal Health Group Plc
- Insiders 16.37%
- Institutions 65.98%
- Public & others 17.65%
- Shares outstanding 66.7M
- Free float 59.3M
Eco Animal Health Group Plc company profile
- Company name
- Eco Animal Health Group Plc
- Ticker
- EAH.LSE
- ISIN
- GB0032036807
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 213
- Fiscal year end
- March
- Address
- The Grange, London, United Kingdom, N14 6BN
- Phone
- 44 208 447 8899
- Website
- ecoanimalhealth.com
About Eco Animal Health Group Plc
ECO Animal Health Group plc, together with its subsidiaries, manufactured and supply animal health products internationally. The company provides Aivlosin, a macrolide antibiotic for the treatment of enteric and respiratory diseases in pigs and poultry. It also offers Ecomectin to treat parasites in cattle, sheep, and pigs; and ECOVAXXIN MS, a mycoplasma solution. ECO Animal Health Group plc was founded in 1972 and is based in London, the United Kingdom.
Eco Animal Health Group Plc management
4- Dr. David Charles HallasCEO & Director · born 1964
- Mr. Christopher John Wilks ACA, BSc, F.C.A.CFO, Finance Director, Secretary & Director · born 1964
- Mr. Andrew BuglassChief Commercial Officer
- Dr. Andrew WinderHead of Business Development